NASDAQ$JBIO
Jade Biosciences Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Announced financial results for the second quarter of 2022.
Aerovate Therapeutics reported a net loss of $12.0 million for the second quarter ended June 30, 2022, compared to a net loss of $5.8 million for the second quarter ended June 30, 2021. As of June 30, 2022, cash, cash equivalents and short-term investments totaled $152.0 million.
- Continued progress for IMPAHCT global Phase 2b/Phase 3 clinical trial.
- Presented Phase 1 results at ATS, showing AV-101 was generally well-tolerated.
- Expanded intellectual property portfolio with new patents issued and notices of allowance received.
- Strengthened management team with the addition of Stephen Yu as Senior Vice President, Quality.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Forward guidance
Aerovate expects that its cash, cash equivalents and short-term investments will be sufficient to fund operations into the second half of 2025, based on the current operating plan.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro